Targeting CNDP2 may be particularly beneficial for lung cancer patients that frequently carry mutations in the KEAP1 gene, as KEAP1 deficiency rendered cells more reliant on this cooperation. The gene discussed is KEAP1; the disease is lung carcinoma.